Life Sciences, Biotech and Pharma: A Look at Capital Flow and M&A Activity in Trending Sectors
Presented By: Smart Business
A group of dynamic female entrepreneurs and savvy investors explore rising trends in dealmaking within three hot Philadelphia sectors: life sciences, biotech and pharma. They’ll share personal experiences and discuss what’s spurring activity, who’s active and where the money is flowing.
Co-Founder & Managing Partner
Blue Highway Capital
Christine Jones is managing partner of Blue Highway Capital, formed to stimulate and reinforce the growth of small companies in rural and other underserved areas. She has 25 years of expertise sourcing, structuring and managing 24 investments in small middle-market companies across a broad range of industries including business services, health care services, telecommunications, transportation and logistics, consumer products and manufacturing. Blue Highway is currently investing $2 million to $4 million in growth equity for companies with revenues of $5 million to $50 million.
Co-Founder, CAO, and CFO
RTM Vital Signs
Denise L. Devine, CPA, MBA, MST, is an experienced independent board director. Her experience spans from entrepreneurial startups to Fortune100 corporations. She is founder and CEO of FNB Holdings LLC, a company dedicated to initiatives in the health and wellness space, and a founder, CAO and CFO of RTM Vital Signs LLC, an early stage medical device company.
President & CEO
Gerri Henwood has served as president and CEO, and a director of Recro Pharma — a revenue-generating, specialty pharmaceutical company — since its inception in 2008. From 2006 to 2013, she served as president of Malvern Consulting Group Inc., a pharmaceutical incubator and consulting firm. She continues to spend a small amount of time engaged in the provision of consulting services for MCG to other companies.
Adele Oliva has been a health care investor for over 20 years, focusing on commercial stage medical technology, health care service and specialty therapeutic investments. She co-founded 1315 Capital in 2014 to establish a firm focused on health care growth investing, and it has since raised two funds and has over $500 million under management. She currently serves on the boards of Colorescience, Encore Dermatology, Innovative Health, NovaSom, Onkos Surgical and TELA Bio.
Founder, President & CEO
Dr. Ellen “Ellie” Stang is a board-certified pediatrician who, in 2003, founded ProgenyHealth® to address the need for improved care management and health outcomes for premature and medically complex newborns. As president, CEO and a member of the board, Stang leads ProgenyHealth as it works with thousands of NICUs in all 50 states. The company is a recognized leader in deploying evidence-based neonatal care management services.